PBI 4050

Drug Profile

PBI 4050

Alternative Names: PBI-4050

Latest Information Update: 27 Jan 2017

Price : $50

At a glance

  • Originator ProMetic Life Sciences
  • Developer ProMetic Life Sciences; Vanderbilt University
  • Class Anti-inflammatories; Antifibrotics; Small molecules
  • Mechanism of Action Cell differentiation modulators; Colony stimulating factor stimulants; Cytokine modulators; Erythropoiesis stimulants; Extracellular matrix protein inhibitors; Extracellular matrix protein modulators; Immunomodulators; Inflammation mediator inhibitors; Inflammation mediator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Inborn genetic disorders; Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic nephropathies; Idiopathic pulmonary fibrosis; Inborn genetic disorders; Metabolic syndrome
  • Preclinical Cystic fibrosis; Pulmonary arterial hypertension; Renal fibrosis; Scleroderma
  • No development reported Anaemia; Haematological disorders; Neutropenia

Most Recent Events

  • 24 Jan 2017 The UK Medicines and Healthcare Products Regulatory Agency designates Promising Innovative Medicine (PIM) status to PBI 4050 for Inborn genetic disorders (Alstrom syndrome) in United Kingdom
  • 18 Jan 2017 PBI 4050 receives Orphan Drug status for Inborn genetic disorders (Alstrom syndrome) in Europe
  • 21 Nov 2016 ProMetic initiates enrolment in a phase II trial for Idiopathic pulmonary fibrosis in Canada before November 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top